April 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Sumitomo Pharmaceuticals to Transfer Its Antitumor Antibiotic Sales to Nippon Kayaku
 

Tokyo, Jan 18, 2005 (JCN) - Sumitomo Pharmaceuticals has announced that it has signed a memorandum on the transfer of sales of its proprietary antitumor drug Calsed with Nippon Kayaku (TSE: 4272).

Under the terms of the memorandum, Sumitomo Pharmaceuticals will transfer the sales of Calsed to Nippon Kayaku. In addition, the two companies will collaborate in post-marketing surveillance studies.

Calsed, an anthracycline antitumor agent, has been widely used in the treatments of small-cell and non-small-cell lung cancers since its release in December 2002.

Currently, Sumitomo Pharmaceuticals has conducted clinical trials for malignant lymphoma. Nippon Kayaku plans to launch sales operations this spring.

By Dale Hug Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Nippon Kayaku Co., Ltd. News  
  KAYAKU, JAXA Develop Highly Efficient Electric Aviation Motor Coil  (May 31, 2013)
  Nippon Kayaku Seeking Additional Approval for Antitumor Agent  (July 4, 2006)
  Shionogi, Nippon Kayaku Receive Approval for Cetrotide  (Apr 21, 2006)
  Nippon Kayaku to Merge Two Consolidated Subsidiaries in June  (Mar 2, 2006)
  Nippon Kayaku Obtains Additional Approval for Its Three Anti-tumor Agents  (Feb 23, 2005)
  Yamanouchi Pharmaceutical to License Gelpart Coronary Embolism Material to Nippon Kayaku  (Feb 9, 2005)
  Sumitomo Pharmaceuticals to Transfer Its Antitumor Antibiotic Sales to Nippon Kayaku  (Jan 18, 2005)
  New Expanded Indication for Nippon Kayaku's Exal Offers Additional Treatment Option for Refractory Germ Cell Tumors  (Dec 21, 2004)
  Nippon Kayaku, DHF and TTC Establish New Company for Innovative Cancer Treatment  (Jan 26, 2004)
  Nippon Kayaku to Acquire Rights to Import and Distribute Eli Lilly Japan's Vincristine Sulfate Products  (Jan 14, 2004)



 Recent  Drugs & OTC News   
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)